ZA201104701B - Method for treating parkinson's disease using filamentous bacteriophage - Google Patents

Method for treating parkinson's disease using filamentous bacteriophage

Info

Publication number
ZA201104701B
ZA201104701B ZA2011/04701A ZA201104701A ZA201104701B ZA 201104701 B ZA201104701 B ZA 201104701B ZA 2011/04701 A ZA2011/04701 A ZA 2011/04701A ZA 201104701 A ZA201104701 A ZA 201104701A ZA 201104701 B ZA201104701 B ZA 201104701B
Authority
ZA
South Africa
Prior art keywords
disease
treating parkinson
filamentous bacteriophage
filamentous
bacteriophage
Prior art date
Application number
ZA2011/04701A
Other languages
English (en)
Inventor
Beka Solomon
Haim M Dimant
Original Assignee
Ramot At Tel-Aviv Univ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel-Aviv Univ Ltd filed Critical Ramot At Tel-Aviv Univ Ltd
Publication of ZA201104701B publication Critical patent/ZA201104701B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/14011Details ssDNA Bacteriophages
    • C12N2795/14111Inoviridae
    • C12N2795/14132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/14011Details ssDNA Bacteriophages
    • C12N2795/14111Inoviridae
    • C12N2795/14171Demonstrated in vivo effect
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA2011/04701A 2008-11-24 2011-06-24 Method for treating parkinson's disease using filamentous bacteriophage ZA201104701B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11744608P 2008-11-24 2008-11-24
PCT/US2009/065659 WO2010060073A2 (en) 2008-11-24 2009-11-24 Method for treating parkinson's disease

Publications (1)

Publication Number Publication Date
ZA201104701B true ZA201104701B (en) 2012-09-26

Family

ID=41572327

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/04701A ZA201104701B (en) 2008-11-24 2011-06-24 Method for treating parkinson's disease using filamentous bacteriophage

Country Status (16)

Country Link
US (1) US20110286970A1 (enExample)
EP (2) EP2478911A1 (enExample)
JP (1) JP2012509672A (enExample)
KR (1) KR20110091778A (enExample)
CN (1) CN102223887B (enExample)
AU (1) AU2009316326A1 (enExample)
BR (1) BRPI0921557A2 (enExample)
CA (1) CA2744339A1 (enExample)
CO (1) CO6390112A2 (enExample)
IL (1) IL213120A0 (enExample)
MX (1) MX2011005430A (enExample)
NZ (1) NZ592928A (enExample)
RU (1) RU2011125971A (enExample)
SG (1) SG171791A1 (enExample)
WO (1) WO2010060073A2 (enExample)
ZA (1) ZA201104701B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555128T1 (de) 2006-11-30 2012-05-15 Res Dev Foundation Verbesserte immunglobulin-bibliotheken
WO2009143470A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque
CA2829223A1 (en) 2011-03-11 2012-09-20 Beka Solomon Method for treating neurodegenerative tauopathy
EP2736522A1 (en) 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
CN104093414A (zh) * 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
TWI613212B (zh) 2012-10-02 2018-02-01 波克萊拉生物科技股份有限公司 作爲澱粉樣蛋白結合劑之g3p融合蛋白
AU2014274253B2 (en) 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
EA201791212A1 (ru) 2014-12-03 2018-01-31 Проклара Байосайенсиз, Инк. Полипептиды, содержащие аминокислотную последовательность модифицированного бактериофага g3p, в которой отсутствует сигнал гликозилирования

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344189T3 (es) * 1999-09-03 2010-08-20 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer.
AU2002223886A1 (en) * 2000-11-24 2002-06-03 Isis Innovation Limited Mixed fibrils
ES2392247T3 (es) * 2002-03-05 2012-12-07 Ramot At Tel-Aviv University Ltd. Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
EP1853299A4 (en) * 2005-01-14 2009-11-11 Univ California COMPOSITIONS AND METHODS FOR INHIBITING THE PRESENCE OF DRUGS AND DIAGNOSING OR TREATING DRUG-INDUCED DISEASES
ES2363203T3 (es) * 2005-02-01 2011-07-26 Ramot At Tel-Aviv University Ltd. Método para tratar una inflamación asociada a depósitos amiloides y una inflamación cerebral que implica una microglia activada.
BRPI0707871A2 (pt) * 2006-02-15 2011-05-10 Ramot At Tel Aviv University veÍculos de exibiÇço de fago, composiÇço farmacÊutica ,e, mÉtodos para o tratamento ou a inbiÇço e para o diagnàsticos de uma doenÇa, distébio ou condiÇço cerebral
CA2659032A1 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
WO2009143470A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque

Also Published As

Publication number Publication date
JP2012509672A (ja) 2012-04-26
US20110286970A1 (en) 2011-11-24
KR20110091778A (ko) 2011-08-12
WO2010060073A3 (en) 2010-09-02
AU2009316326A1 (en) 2010-05-27
BRPI0921557A2 (pt) 2019-09-24
NZ592928A (en) 2012-12-21
SG171791A1 (en) 2011-07-28
IL213120A0 (en) 2011-07-31
CO6390112A2 (es) 2012-02-29
RU2011125971A (ru) 2012-12-27
WO2010060073A2 (en) 2010-05-27
EP2358377A2 (en) 2011-08-24
CA2744339A1 (en) 2010-05-27
HK1162964A1 (en) 2012-09-07
CN102223887B (zh) 2013-11-06
EP2478911A1 (en) 2012-07-25
MX2011005430A (es) 2011-10-28
CN102223887A (zh) 2011-10-19

Similar Documents

Publication Publication Date Title
GB2465897B (en) Respiratory disease treatment
IL209896A0 (en) Compounds for treating symptoms associated with parkinson's disease
ZA201008484B (en) Rasagiline for parkinson's disease modification
ZA201002751B (en) Compositions for treating parkinson's disease
PT2324126E (pt) Método de identificação de factores de risco da doença de alzheimer
ZA201007216B (en) Agent for treating disease
IL207892A0 (en) Agent for treating disease
IL207891A0 (en) Agent for treating disease
PL2985032T3 (pl) Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
EP2485733A4 (en) METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PL2350279T3 (pl) Sposoby leczenia chorób oczu
ZA200702027B (en) Process for relaxing or straightening hair
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
IL213120A0 (en) Method for treating parkinson' s disease
PL2131841T3 (pl) Sposoby leczenia bólu ostrego
PT2341937E (pt) Composição para tratamento de doença
EP2255825A4 (en) COMPOSITION FOR PREVENTING OR TREATING BRAIN DISEASES
IL217149A0 (en) Compositions and methods for treating parkinson's disease
EP2517698A4 (en) ACTIVE AGENT FOR THE TREATMENT OF MORBUS PARKINSON
EP2517704A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND METHOD OF MAKING SAME
GB0701456D0 (en) Treatment for respiratory disease
EP1863510A4 (en) METHOD FOR TREATING PARKINSON DISEASE
HK1175364A (en) Methods for treating parkinson's disease
GB0823568D0 (en) Respiratory disease treatment
GB0814488D0 (en) Respiratory disease treatment